BiomX Toekomstige groei

Future criteriumcontroles 0/6

De winst van BiomX zal naar verwachting dalen met 24.5% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 100.3% per jaar. De winst per aandeel zal naar verwachting afnemen met 9.8% per jaar.

Belangrijke informatie

-24.5%

Groei van de winst

-9.8%

Groei van de winst per aandeel

Biotechs winstgroei	28.3%
Inkomstengroei	100.3%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	15 Nov 2024

Recente toekomstige groei-updates

Recent updates

What Kind Of Shareholders Own BiomX Inc. (NYSEMKT:PHGE)?

Jan 29

Winst- en omzetgroeiprognoses

NYSEAM:PHGE - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-48	N/A	N/A	2
12/31/2025	N/A	-41	N/A	N/A	2
12/31/2024	N/A	-30	N/A	N/A	2
9/30/2024	N/A	-9	N/A	N/A	N/A
6/30/2024	N/A	-26	-35	-35	N/A
3/31/2024	N/A	-34	-28	-28	N/A
12/31/2023	N/A	-26	-21	-21	N/A
9/30/2023	N/A	-27	-22	-22	N/A
6/30/2023	N/A	-25	-22	-22	N/A
3/31/2023	N/A	-27	-27	-27	N/A
12/31/2022	N/A	-28	-29	-29	N/A
9/30/2022	N/A	-33	-31	-31	N/A
6/30/2022	N/A	-36	-33	-31	N/A
3/31/2022	N/A	-36	-31	-29	N/A
12/31/2021	N/A	-36	-31	-28	N/A
9/30/2021	N/A	-35	-30	-26	N/A
6/30/2021	N/A	-34	-29	-26	N/A
3/31/2021	N/A	-33	-26	-24	N/A
12/31/2020	N/A	-30	-25	-24	N/A
9/30/2020	N/A	-27	-25	-24	N/A
6/30/2020	N/A	-23	-24	-23	N/A
3/31/2020	N/A	-22	-23	-21	N/A
12/31/2019	N/A	-21	-19	-18	N/A
9/30/2019	N/A	-22	-15	-14	N/A
6/30/2019	N/A	-19	-13	-12	N/A
3/31/2019	N/A	-17	-12	-12	N/A
12/31/2018	N/A	-15	-11	-11	N/A
12/31/2017	N/A	-7	N/A	-4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat PHGE de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat PHGE de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat PHGE de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat PHGE volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat PHGE volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PHGE naar verwachting over 3 jaar hoog zal zijn

BiomX Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased to US$10.25

Price target decreased to US$19.00

Recent updates

New major risk - Market cap size

BiomX Files Form 15

BiomX Inc. to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

Biomx Inc. to Present Positive Phase 1B/2A Clinical Trial Data for Bx004 At the European Respiratory Society (Ers) Congress 2024

New major risk - Financial position

High number of new directors

BiomX Announces NYSE American Acceptance of Plan to Regain Listing Compliance

BiomX Inc., Annual General Meeting, Jul 09, 2024

BiomX Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

BiomX Inc. to Report Q1, 2024 Results on May 21, 2024

Biomx Inc. Appoints Susan Blum to Its Board of Directors and Member and Chair of the Audit Committee of the Board

BiomX Inc. announced delayed annual 10-K filing

BiomX Inc. announced that it has received $50.013969 million in funding from Deerfield Management Company, LLC, AMR Action Fund GP, LLC, Cystic Fibrosis Foundation, Nantahala Capital Management, LLC, OrbiMed Advisors LLC

BiomX Inc. announced that it expects to receive $50.013969 million in funding

BiomX Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Biomx Announces Positive Topline Results from Part 2 of the Phase 1B/2A Trial Evaluating Bx004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Biomx to Present Data from Ongoing Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis

BiomX Inc. Announces the Appointment of Edward L. Williams to its Board of Directors

BiomX Inc. Announces Completion of Patient Dosing in Part 2 of Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Biomx Inc. to Present Part 1 Data from Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session At The46th European Cystic Fibrosis Conference

Biomx Inc. Appoints Jason M. Marks and Michael E. Dambach to the Board of Directors

BiomX Inc. Announces Board Resignations

BiomX Inc. Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease

BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange

BiomX Inc. Announces Dosing of the First Two Patients in Phase 1B/2A Study of Bx004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

BiomX Inc., Annual General Meeting, Aug 24, 2022

Price target decreased to US$10.25

BiomX Inc. to Report Q1, 2022 Results on May 11, 2022

CF Foundation Awards Up to $5 Million to BiomX for Potential Phage Therapy

Price target decreased to US$19.00

High number of new directors

BiomX Inc. announced delayed 10-Q filing

BiomX Inc. Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin

New 90-day high: US$8.40

New 90-day high: US$7.11

BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy

What Kind Of Shareholders Own BiomX Inc. (NYSEMKT:PHGE)?

New 90-day high: US$6.97

BiomX Inc. Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer

New 90-day high: US$6.67

BiomX Inc. Presents Preclinical Results of Phage Targeting Klebsiella Pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

BiomX Inc. to Report Q3, 2020 Results on Nov 12, 2020

BiomX Reports Appointment of Paul Sekhri and Alan Moses to Its Board of Directors

Biomx Inc. Announces Changes to Its Board

New 90-day high - US$8.00

BiomX Inc. to Report Q2, 2020 Results on Aug 13, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven